SCHEMBL3235348

SCHEMBL3235348

CCOc1ccc2c(c1)C(C)(c1cc(C(=O)NCCCN(C)C)ccc1Cl)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AVPR1A P37288 4/20 0.51
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
RAB9A P51151 1/20 0.36
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
TDP1 Q9NUW8 2/20 0.35
CHEK1 O14757 1/20 0.35
DAPK3 O43293 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
PAK4 O96013 1/20 0.35
ABL1 P00519 1/20 0.35
LCK P06239 1/20 0.35
RET P07949 1/20 0.35
MET P08581 1/20 0.35
PDGFRB P09619 1/20 0.35
PIM1 P11309 1/20 0.35
PDGFRA P16234 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3232071 0.92 AVPR1A (0.51) AVPR1AKMT2ARAB9AALDH1A1CYP3A4
SCHEMBL3231628 0.91 AVPR1A (0.53) AVPR1AMEN1KMT2ARAB9ACYP3A4
SCHEMBL3233606 0.91 AVPR1A (0.55) AVPR1AMEN1KMT2ARAB9ATDP1
SCHEMBL3239294 0.89 AVPR1A (0.56) AVPR1ARAB9AALDH1A1CYP2C9DRD2
SCHEMBL3233637 0.89 AVPR1A (0.55) AVPR1AMEN1KMT2AAVPR1BOXTR
SCHEMBL3234052 0.88 AVPR1A (0.55) AVPR1AMEN1KMT2AAVPR1BOXTR
SCHEMBL3227252 0.88 AVPR1A (0.57) AVPR1AKMT2ARAB9AALDH1A1AVPR1B
SCHEMBL3229122 0.87 AVPR1A (0.49) AVPR1AMEN1KMT2ARAB9AALDH1A1
SCHEMBL3235137 0.87 AVPR1A (0.57) AVPR1AMEN1KMT2ARAB9AALDH1A1
SCHEMBL3230051 0.87 AVPR1A (0.55) AVPR1AMEN1KMT2ARAB9AAVPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097374-B1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS SANOFI AVENTIS (FR) 2010-06-09 EP claimed
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY SANOFI-AVENTIS (FR) 2010-03-18 US claimed
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY SANOFI-AVENTIS (FR) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AVPR2, AVPR1A, AVPR1B AVPR1A 2/4885MEN1 1684/4885KMT2A 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.